Lonza has expanded a clinical manufacturing agreement with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders. The agreement covers development and manufacturing for LAD-I, a phase 1/2 candidate for the treatment of Leukocyte Adhesion Deficiency-I (LAD-I).   The companies have been working together since 2018 and decided to make the collaboration public in parallel to the successful preliminary data ...